



# GLAND PHARMA LIMITED

August 30, 2024

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

**Sub: Change(s) in Directorate**

**Ref: Announcements made on August 07, 2024 & August 26, 2024**

In compliance of the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to the disclosures made by the Company dated August 07, 2024 and August 26, 2024; we would like to inform you regarding the changes among the Board of Directors of the Company, as approved by the shareholders of the Company in the 46<sup>th</sup> Annual General Meeting held on August 30, 2024 as specified below:

1. Mr. Yao Fang (DIN: 09524705) ceased to be the Non-Executive and Non-Independent Director of the Company with effect from August 30, 2024; as he did not offer himself for reappointment and accordingly, retired from his office as a Director.

The Board of Directors of the Company and the entire Gland Pharma family places on record their deep sense of appreciation for the contribution of Mr. Yao Fang towards the success of the Company.

2. Mr. Qiyu Chen (DIN: 07675421) ceased to be the Non-Executive and Non-Independent Director of the Company with effect from August 30, 2024; as he hasn't yet received the Security Clearance from the Government of India and accordingly he ceased to be the Director of the Company in compliance of the provisions of the Regulation 17(1D) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Qiyu Chen has been associated with the Company since October 03, 2017 and has been a strong force in heralding the Company in achieving its excellence. The Board of Directors of the Company and the entire Gland Pharma family places on record their deep sense of appreciation for the long-standing leadership and contribution of Mr. Qiyu Chen during his tenure towards the growth of the Company.

3. Mr. Wenjie Zhang (DIN: 10727581), who has consented to act as a Non-Executive and Non-Independent Director of the Company, liable to retire by rotation assumed his office with effect from August 30, 2024, pursuant to the resolution passed by the shareholders of the Company in the 46<sup>th</sup> Annual General Meeting of the Company held on August 30, 2024.

**Regd. Office:**  
Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads  
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal  
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India  
Tel: +91-40-30510999 Fax: +91-40-30510800

**Corporate Office:**  
Plot No. 11 & 84, TSIC Phase: IV  
Pashamylaram (V), Patancheru (M), Sangareddy District  
Hyderabad 502307, Telangana, India  
Tel: +91-8455-699999



The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in **Annexure-A** enclosed herewith.

This is for your information and records.

**Yours truly,  
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi  
Company Secretary & Compliance Officer**

**Encl:** As above

**Annexure A**

**Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

**1. Details of Mr. Yao Fang**

<b>SI. No</b>	<b>Particulars</b>	<b>Remarks</b>
1	Reason for change	Mr. Yao Fang ceased to be the Non-Executive and Non-Independent Director of the Company as he did not offer himself for reappointment and accordingly, he retired from his office as a Director.
2	Date of Change	30.08.2024
3	Brief profile	Not Applicable
4	Disclosure of relationships between director	Not Applicable

**2. Details of Mr. Qiyu Chen**

<b>SI. No</b>	<b>Particulars</b>	<b>Remarks</b>
1	Reason for change	Mr. Qiyu Chen ceased to be the Non-Executive and Non-Independent Director of the Company as he hasn't yet received the Security Clearance from the Government of India.
2	Date of Change	30.08.2024
3	Brief profile	Not Applicable
4	Disclosure of relationships between director	Not Applicable

**3. Details of Mr. Wenjie Zhang**

<b>SI. No</b>	<b>Particulars</b>	<b>Remarks</b>
1	Reason for change	Appointment of Mr. Wenjie Zhang as a Non-Executive and Non-Independent Director of the Company.
2	Date of Change	30.08.2024
3	Brief profile	Mr. Wenjie Zhang is the Executive President and Co-CEO of Innovative Medicines division of Fosun Pharma. He is also the



		<p>Chairman and Executive Director of Shanghai Henlius Biotech Co. Ltd and Chairman of Fosun Kite Biotechnology Co. Ltd.</p> <p>Mr. Wenjie Zhang joined Fosun Pharma Group and served as Senior Vice President, Chief Commercial Operations Officer, Chief Strategic Officer, President, CEO, and Chairman of Shanghai Henlius Biotech Co., Ltd. since March, 2019.</p> <p>Before joining Henlius in March, 2019; Mr. Zhang served as general Manager of Amgen China and also worked as Vice President, Oncology for Roche China from 2010 to 2014.</p> <p>Mr. Zhang holds an MBA degree from Yale University School of Management and a B.S. degree in Microbiology from Shandong University.</p>
4	Disclosure of relationships between director	Not Applicable